Axel Hauschild

Summary

Affiliation: University of Kiel
Country: Germany

Publications

  1. doi Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study
    Axel Hauschild
    Department of Dermatology, University of Schleswig Holstein, Campus Kiel, Kiel, Germany
    Cancer 113:1404-11. 2008
  2. doi Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge
    Eva Beatrice Mohr
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Dermatol Surg 34:1131-6. 2008
  3. doi Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy
    Axel Hauschild
    Department of Dermatology, University Clinic Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 6:829-37, 829-38. 2008
  4. doi Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:152-60. 2008
  5. ncbi [Modern treatment modalities in actinic keratoses of the skin]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Dtsch Med Wochenschr 131:447-52. 2006
  6. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  7. ncbi [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Schittenhelmstrasse 7, 24105 Kiel
    Hautarzt 57:764-72. 2006
  8. doi Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
    Axel Hauschild
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, D 24105 Kiel
    J Clin Oncol 28:841-6. 2010
  9. ncbi Treatment of actinic cheilitis using photodynamic therapy with methyl aminolevulinate: report of three cases
    Axel Hauschild
    Department of Dermatology, University Hospital Schleswig Holstein, Schittenhelmstrasse 7, 24105 Kiel, Germany
    Dermatol Surg 31:1344-7, discussion 1348. 2005
  10. ncbi [Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]
    Axel Hauschild
    Klinik und für Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Kiel
    J Dtsch Dermatol Ges 4:508-10. 2006

Detail Information

Publications110 found, 100 shown here

  1. doi Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study
    Axel Hauschild
    Department of Dermatology, University of Schleswig Holstein, Campus Kiel, Kiel, Germany
    Cancer 113:1404-11. 2008
    ..To the authors' knowledge, the current study is the first to test a combination of these 2 agents in a phase 2 trial...
  2. doi Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge
    Eva Beatrice Mohr
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Dermatol Surg 34:1131-6. 2008
  3. doi Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy
    Axel Hauschild
    Department of Dermatology, University Clinic Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 6:829-37, 829-38. 2008
    ..This review covers the pathomechanisms, incidence and optimized therapy of IFN-alpha-associated side effects...
  4. doi Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:152-60. 2008
    ..An urgent need for development of new treatment modalities is necessary and general principles of experimental immunotherapy are outlined...
  5. ncbi [Modern treatment modalities in actinic keratoses of the skin]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Dtsch Med Wochenschr 131:447-52. 2006
    ..This overview will report on the actual treatment opportunities and a careful consideration in the year 2006...
  6. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  7. ncbi [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Schittenhelmstrasse 7, 24105 Kiel
    Hautarzt 57:764-72. 2006
    ..Indiscriminate use of newer therapeutic approaches is simply not affordable in this age of shrinking financial resources for health care...
  8. doi Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
    Axel Hauschild
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, D 24105 Kiel
    J Clin Oncol 28:841-6. 2010
    ..86; HR, 1.03; 95% CI, 0.71 to 1.50) showed significant differences. CONCLUSION A prolongation of conventional LDI therapy from 18 to 60 months showed no clinical benefit in patients with intermediate and high-risk primary melanoma...
  9. ncbi Treatment of actinic cheilitis using photodynamic therapy with methyl aminolevulinate: report of three cases
    Axel Hauschild
    Department of Dermatology, University Hospital Schleswig Holstein, Schittenhelmstrasse 7, 24105 Kiel, Germany
    Dermatol Surg 31:1344-7, discussion 1348. 2005
    ....
  10. ncbi [Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]
    Axel Hauschild
    Klinik und für Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Kiel
    J Dtsch Dermatol Ges 4:508-10. 2006
  11. ncbi Individualized therapy of disseminated cancer using malignant melanoma as a model
    Axel Hauschild
    Department of Dermatology, University of Kiel, Kiel, Germany
    Cancer Metastasis Rev 25:253-6. 2006
    ..This article will give an overview of recent developments in clinical trials of targeted therapies in metastatic melanoma patients...
  12. doi Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
    Axel Hauschild
    Department of Dermatology, University Hospital of Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, D 24105 Kiel, Germany
    J Clin Oncol 27:3496-502. 2009
    ..2% (arm A) and 82.9% (arm B). CONCLUSION The addition of a 4-week modified HDI induction phase to a 2-year low-dose adjuvant IFN-alpha-2b treatment schedule did not improve the clinical outcome...
  13. ncbi [Melanocytic nevi]
    Axel Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig Holstein Campus Kiel
    J Dtsch Dermatol Ges 4:686-97. 2006
  14. ncbi [Clinical studies with sorafenib (Nexavar) in metastatic melanoma]
    Axel Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Keil, Germany
    J Dtsch Dermatol Ges 5:345. 2007
  15. doi Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies
    A Hauschild
    Department of Dermatology, Venereology and Allergology, University of Kiel, Schittenhelmstr 7, D 24105 Kiel, Germany
    Br J Dermatol 160:1066-74. 2009
    ..Photodynamic therapy (PDT) is increasingly used for treatment of actinic keratoses (AKs) but is a cumbersome procedure. A thin self-adhesive patch (PD P 506 A) containing 5-aminolaevulinic acid (5-ALA) was developed to facilitate PDT...
  16. ncbi [EADV-Conference 16.-20.05.2007 in Vienna: Study of new pharmaceuticals 5-ALAPlaster (PD P 506 A)]]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 5:815. 2007
  17. ncbi [Systemic treatment of melanoma. Current clinical trials]
    A Hauschild
    Schwerpunktbereich Dermato Onkologie und Operative Dermatologie, Klinik fur Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig Holstein Campus Kiel, Kiel, Deutschland
    Hautarzt 59:484-91. 2008
    ..This overview delineates the most important clinical trials currently conducted or planned in the adjuvant and palliative setting of melanoma treatment...
  18. doi Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch
    Axel Hauschild
    Department of Dermatology, Allergology and Venerology, University of Kiel, Kiel, Germany
    Exp Dermatol 18:116-21. 2009
    ..Photodynamic therapy (PDT) is increasingly used for the treatment of actinic keratosis (AK)...
  19. doi Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
    Axel Hauschild
    Department of Dermatology, University of Kiel bCharité University Medicine Berlin, Germany
    Melanoma Res 18:274-8. 2008
    ..Single-agent treatment with MS-275 was well-tolerated and showed long-term tumor stabilizations, but no objective responses in pretreated metastatic melanoma. Further evaluation of MS-275 in combination schedules is warranted...
  20. ncbi [Meeting report of the 39th Annual Conference of the American Society of Clinical Oncology (ASCO), 5/31-6/3/2003, Chicago, USA]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Hautarzt 54:999-1002. 2003
  21. ncbi Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis
    Axel Hauschild
    Department of Dermatology, University of Kiel, St Georg Hospital, Hamburg, Germany
    J Clin Oncol 21:2883-8. 2003
    ..We hypothesized that a combination regimen with low-dose interleukin-2 (IL-2) may improve survival prospects in these patients...
  22. ncbi [Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials]
    A Hauschild
    Universitäts Hautklinik Kiel
    Hautarzt 52:1003-10. 2001
    ..This article should serve as a basis of discussion for the proposed revision of the current guidelines of the German Dermatologic Society (DDG) on the primary surgical care of melanoma patients...
  23. ncbi Surgical standards in the primary care of melanoma patients
    A Hauschild
    Department of Dermatology, University of Kiel, Germany
    Onkologie 26:218-22. 2003
    ..However, it is unclear whether sentinel node biopsy is of benefit for a better survival in affected patients...
  24. ncbi Sentinel node biopsy in melanoma
    A Hauschild
    Department of Dermatology, University of Kiel, Germany
    Virchows Arch 438:99-106. 2001
    ..The clinical value of reverse-transcriptase polymerase chain reaction (RT-PCR)based search for minimal melanoma disease in lymph nodes remains unclear...
  25. ncbi [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma]
    A Hauschild
    Klinik fur Dermatologie, Venerologie und Allergologie, Christian Albrechts Universitat zu Kiel
    Laryngorhinootologie 79:428-33. 2000
    ..Adjuvant chemotherapy has not shown a clinically relevant benefit. Thus, patients should preferentially be treated within controlled clinical trials...
  26. doi Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial
    Maja A Hofmann
    Department of Dermatology, Charite Universitatsmedizin, Berlin, Germany
    Melanoma Res 21:516-23. 2011
    ..Interestingly, having the choice of chemotherapy or BSC alone in a second-line situation, more than 70% of patients chose polychemotherapy...
  27. doi Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse
    Friederike Egberts
    Department of Dermatology, Campus Kiel, University Hospital of Schleswig Holstein, Kiel 24105, Germany
    Melanoma Res 19:31-5. 2009
    ..Both markers, LDH and S-100B, are not able to identify loco-regional metastases with a low tumor load in high-risk melanoma patients...
  28. ncbi Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients
    Friederike Egberts
    Department of Dermatology, Schleswig Holstein University Hospital, Campus Kiel, Germany
    Anticancer Res 30:1799-805. 2010
    ..The purpose of this study was to determine the value of serum S-100B and LDH in melanoma patients prior to sentinel lymph node dissection (SLND) with respect to the clinical outcome...
  29. doi Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH
    Friederike Egberts
    Department of Dermatology, University Hospital of Schleswig Holstein, Campus Kiel, Germany
    Onkologie 31:380-4. 2008
    ..The prognostic importance of S100B serum levels on overall survival compared to lactate dehydrogenase (LDH) was evaluated...
  30. ncbi New promises in the adjuvant, and palliative treatment of melanoma
    Axel Hauschild
    Department of Dermatology, University of Kiel, Kiel, Germany
    Cancer Treat Res 135:277-92. 2007
  31. ncbi Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group
    Thomas K Eigentler
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 18:353-8. 2008
    ..Thus, this randomized trial did not confirm earlier reports of beneficial effects of adjuvant vindesine and can therefore not be recommended...
  32. doi Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma
    Katharina C Kaehler
    Department of Dermatology, University of Kiel, Kiel, Germany
    Eur J Cancer 46:41-6. 2010
    ..The use of pegylated interferons in earlier stage melanomas will be investigated in upcoming trials...
  33. pmc The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
    Caroline J Voskens
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    PLoS ONE 8:e53745. 2013
    ..To facilitate timely identification and adequate management data on rare AEs were analyzed at 19 skin cancer centers...
  34. doi Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient
    Friederike Egberts
    Department of Dermatology, University Hospital Schleswig Holstein, Kiel, Germany
    J Am Acad Dermatol 58:880-4. 2008
    ..The atypical clinical and histopathologic appearance of the melanocytic lesions as well as the course of disease may have been influenced by the immunosuppression...
  35. doi Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
    Claus Garbe
    Center for Dermatooncology, Department of Dermatology, 72076 Tubingen, Germany
    Eur J Cancer 46:270-83. 2010
    ..In the absence of surgical options, systemic medical treatment is indicated, but with, to date, low response rates. Therapeutic decisions should be made by the melanoma team and the informed patient after full discussion of the options...
  36. doi Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma
    Friederike Egberts
    Department of Dermatology, Schleswig Holstein University Hospital, Campus Kiel, Germany
    Eur J Cancer 48:695-702. 2012
    ....
  37. ncbi Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial
    Karsten Neuber
    Department of Dermatology, University Hospital Hamburg, Martinistr 52, D 20246 Hamburg, Germany
    Melanoma Res 13:81-5. 2003
    ..The non-haematological toxicity of this outpatient regimen was mild. In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma...
  38. ncbi Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management
    Katharina C Kaehler
    Department of Dermatology and Skin Cancer Center, University Hospital Schleswig Holtstein, Campus Kiel, Germany
    Semin Oncol 37:485-98. 2010
    ..This review gives a condensed overview on the mechanisms of action, an update on clinical data of the two CTLA-4 antibodies, ipilimumab and tremelimumab, and detailed recommendations for adverse event management strategies...
  39. doi Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
    Axel Hauschild
    University of Kiel, Kiel, Charite Berlin
    J Clin Oncol 27:2823-30. 2009
    ....
  40. doi Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature
    Katharina C Kaehler
    Department of Dermatology, University of Kiel, Kiel, Germany
    Melanoma Res 18:438-42. 2008
    ..Owing to the lack of clinical trials, we recommend that patients be treated according to the existing guidelines for melanoma...
  41. doi Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results
    Friederike Egberts
    Department of Dermatology, University Hospital of Schleswig Holstein, Campus Kiel, Germany
    Onkologie 31:398-403. 2008
    ..However, these data need to be confirmed in prospective randomized phase III trials. Till then, sorafenib remains an interesting but still experimental new agent for melanoma...
  42. ncbi Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
    C Garbe
    Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Ann Oncol 19:1195-201. 2008
    ..The aim of the study was to improve disease-free survival (DFS) and overall survival (OS) with interferon (IFN) alpha2a with or without dacarbazine (DTIC) compared with observation alone...
  43. doi Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"
    Annette Pflugfelder
    Department of Dermatology, University Hospital Tubingen, Germany
    J Dtsch Dermatol Ges 11:1-116, 1-126. 2013
    ..Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years...
  44. ncbi Molecularly targeted therapy for melanoma: current reality and future options
    Jurgen C Becker
    Department of Dermatology, Julius Maximilians University, Wurzburg, Germany
    Cancer 107:2317-27. 2006
    ..Among the possible targets in melanoma are the Ras-MAPK and PI3K/AKT signal transduction pathways, the proteasome, histone deacetylases, methyltransferases, and melanoma-induced angiogenesis...
  45. doi Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors
    Giorgios Papaspyrou
    Department of Otolaryngology, Head and Neck Surgery, Philipps University Marburg, Marburg, Germany
    Melanoma Res 21:475-82. 2011
    ..In this study, we review the literature regarding epidemiology, molecular pathology, and therapy of mucosal melanomas of the head and neck emphasizing c-kit protein inhibiting treatment modalities for tumors carrying c-kit mutations...
  46. ncbi Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion
    Axel Hauschild
    Department of Dermatology, University of Kiel, Kiel, Germany
    Cancer 112:982-94. 2008
    ..Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment...
  47. doi Recent aspects of medical care of malignant melanoma
    Patrick Terheyden
    Department of Dermatology, University Clinic of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    J Dtsch Dermatol Ges 6:868-78, 868-80. 2008
    ..Cytotoxic T-lymphocyte antigen-4 antibodies, multikinase inhibitors, anti-apoptotic strategies and several other approaches are in progress in Phase III trials both as monotherapy as well as in combination with standard chemotherapy...
  48. doi Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician
    Ralf Gutzmer
    Department of Dermatology, Allergy and Venereology, Skin Cancer Center, Hannover Medical School, Germany
    J Dtsch Dermatol Ges 9:195-203. 2011
    ..A panel of German dermatologists developed on the basis of personal experience and current literature consensus recommendations for the management of cutaneous side effects of EGFR inhibitors...
  49. ncbi Kissing melanoma or kissing nevus of the penis?
    Friederike Egberts
    Department of Dermatology and Allergology, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany
    Urology 69:384.e5-7. 2007
    ..Melanoma of the penis is very rare, and the prognosis is poor. This could be the first case of a "kissing melanoma" of the penis reported in published studies...
  50. ncbi Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risks for the fetus?
    Friederike Egberts
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Germany
    J Dtsch Dermatol Ges 4:717-20. 2006
    ..Despite several chemotherapy regimens, she died one year later. An interdisciplinary approach to obtaining informed consent and managing female high risk melanoma patients with potential or present pregnancy is presented...
  51. pmc Systematic review of medical treatment in melanoma: current status and future prospects
    Claus Garbe
    Department of Dermatology, Division of Dermatooncology, University Hospital Tubingen, Liebermeisterstrasse 25, 72076 Tubingen, Germany
    Oncologist 16:5-24. 2011
    ....
  52. ncbi [Amelanotic malignant melanoma of the scalp clinically resembling a proliferating trichilemmal cyst]
    F Rosien
    Klinik fur Dermatologie, Venerologie und Allergologie des Universitätsklinikums Schleswig Holstein, Campus Kiel
    Dtsch Med Wochenschr 128:2360-2. 2003
    ..A 37-year-old woman was admitted with an ulcerated tumor of the scalp together with an enlarged cervical lymph node. The clinical features resembled proliferative trichilemmal cyst...
  53. ncbi Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Department of Dermatology, Mannheim, Germany
    Ann Oncol 17:1592-7. 2006
    ..The purpose of this study was to test a dose-intensified regimen of temozolomide in melanoma patients with brain metastases in a prospective, open-label, multicentre phase II trial...
  54. ncbi Adjuvant therapy in melanoma
    P Mohr
    Department of Dermatology, Elbeklinikum Buxtehude, Germany
    Onkologie 26:227-33. 2003
    ..Patients with high-risk malignant melanoma should preferentially be treated in prospective randomized multicenter trials to give more detailed data for treatment recommendations...
  55. doi Eczematous malignant melanoma: a wolf in sheep's clothing
    Cornelius Mensing
    Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Onkologie 32:206-8. 2009
    ..The clinical diagnosis of amelanotic melanoma is still a challenge...
  56. doi Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    K Spieth
    Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Ann Oncol 19:801-6. 2008
    ....
  57. ncbi Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma
    Uwe Wollina
    Department of Dermatology, Hospital Dresden Friedrichstadt, Friedrichstrasse 41, 01067 Dresden, Germany
    Cancer 98:993-1001. 2003
    ..The objective of this study was to evaluate the efficacy and toxicity of single-agent PEG-DOXO as second-line chemotherapy in patients with CTCL...
  58. doi Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    Axel Hauschild
    University Hospital, Schleswig Holstein, Department of Dermatology, Kiel, Germany
    Lancet 380:358-65. 2012
    ..We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metastatic melanoma...
  59. ncbi Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line
    Bodo Schniewind
    Clinic for General and Thoracic Surgery, and Department of Dermatology, Section of Molecular Oncology of the University Clinics Schleswig Holstein, Kiel, Germany
    Cancer Biol Ther 4:23-7. 2005
    ..In addition, KT293 cells did not express G-CSF-receptor. These observations suggest that paracrine effects of G-CSF-secretion and PLR might promote an aggressive melanoma phenotype, as seen in this patient...
  60. ncbi Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution
    Christian Hoffmann
    II Medizinische Klinik und Poliklinik, Universitatsklinikum Schleswig Holstein, Campus Kiel, Germany
    Onkologie 28:35-7. 2005
    ..Highly active antiretroviral therapy (HAART) has altered the course of most AIDS-related malignancies. There is some evidence that cellular immunity plays an important role in the progression of metastatic melanoma...
  61. doi Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology
    Katharina C Kahler
    Department of Dermatology and Venereology, UKSH, Kiel, Germany
    J Dtsch Dermatol Ges 7:21-8. 2009
    ..The optimal management of extravasation requires an early diagnosis, the application of specific antidotes and a well-trained oncology team...
  62. doi Giant basal cell carcinoma of the breast mimicking paget's disease: complete remission after photodynamic therapy
    Nadia C Mikhaimer
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    Onkologie 33:613-5. 2010
    ..Basal cell carcinoma (BCC) in the nipple area is extremely rare and can be mistaken for Paget's disease...
  63. ncbi [Current aspects of adjuvant therapy of malignant melanoma]
    K C Kähler
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, Schittenhelmstr 7, 24105, Kiel, Germany
    Hautarzt 61:523-31; quiz 532-3. 2010
    ....
  64. doi Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm
    Friederike Egberts
    Department of Dermatology, Schleswig Holstein University Hospital, Campus Kiel, Schittenhelmstr 7, 24105, Kiel, Germany
    Tumour Biol 31:8-15. 2010
    ..006; HR 3.89; CI 1.48-10.27). In stage I/II melanoma patients, ulceration of the primary tumor was the strongest prognostic factor for RFS, DMFS, and OS and superior to the pathology status of the SN...
  65. ncbi [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]
    S Frick
    Klinik fur Dermatologie, Venerologie und Allergologie der Christian Albrechts Universität zu Kiel, Germany
    Hautarzt 53:659-65. 2002
    ..We treated 25 stage IV patients with temozolomide - a cytostatic drug with 100% oral bioavailability and considerable penetration of CNS tissue...
  66. pmc Telomerase activity in melanocytic lesions: A potential marker of tumor biology
    P Rudolph
    Department of Pathology, University of Kiel, Kiel, Germany
    Am J Pathol 156:1425-32. 2000
    ....
  67. ncbi The sebaceous nevus as part of the Schimmelpenning-Feuerstein-Mims Syndrome--an obvious phacomatosis first documented in 1927
    P H Warnke
    Department of Oral and Maxillofacial Surgery, University of Kiel, Arnold Heller Strasse 16, 24105 Kiel, Germany
    J Cutan Pathol 30:470-2. 2003
    ..We suggest that diagnosis of the SFM syndrome is simple, considering the special linear arrangement of sebaceous nevi in cases of SFM syndrome...
  68. ncbi [Malignant melanoma of the uvula and soft palate]
    C Wolf
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Hautarzt 56:156-9. 2005
    ..Despite aggressive surgical approaches, other treatment options are often limited and usually palliative. Therefore, early diagnosis is critical in patients with mucosal melanoma...
  69. ncbi Intraoral lesions associated with sebaceous nevus syndrome
    P H Warnke
    Department of Oral and Maxillofacial Surgery, University of Kiel, Kiel, Germany
    J Cutan Pathol 33:175-80. 2006
    ..Awareness of the potential presence or development of significant intraoral lesions in association with the sebaceous nevus syndrome is important for those involved in the care of patients with this syndrome...
  70. ncbi Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions
    Thomas K Eigentler
    Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen Department of Dermatology and Venerology, Skin Cancer Center and Center for Integrated Oncology, University Hospital of Cologne, CIO Köln Bonn Department of Dermatology, University Hospital Heidelberg, Heidelberg Department of Dermatology, University Hospital Mainz, Mainz Department of Dermatology, University Essen Duisburg, Essen Department of Dermatology and Allergy, Hannover Medical School, Hannover Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt Main Department of Dermatology, Elbe Kliniken Buxtehude, Buxtehude Medical Department, Technische Universitat, München Department of Dermatology, Zentralklinikum Augsburg, Augsburg Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg Department of Dermatology, University Hospital Muenster, Münster Department of Dermatology, University Hospital Kiel, Kiel Department of Dermatology, University Hospital Homburg Saar, Homburg Saar Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    J Immunother 37:374-81. 2014
    ..Here, the largest ever reported cohort treated with ipilimumab 3 mg/kg alone is described...
  71. doi Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma
    Katharina C Kahler
    Department of Dermatology, Venerology and Allergology, University of Schleswig Holstein Hospital, Campus Kiel, Germany
    J Dtsch Dermatol Ges 9:277-86. 2011
    ..We review the mechanisms of action, provide an update on clinical trials with the two CTLA-4-antibodies for metastatic melanoma, and present detailed recommendations for managing the side effects of these new agents...
  72. doi Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient
    Katharina C Kaehler
    Department of Dermatology, University of Kiel, Germany
    Melanoma Res 19:333-4. 2009
    ..It is important to consider both autoimmune hypophysitis and brain metastasis in the differential diagnosis of melanoma patients receiving CTLA-4 blockade who present this constellation of symptoms...
  73. pmc The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans
    Karin Loser
    Department of Dermatology, University of Munster, Munster, Germany
    PLoS ONE 5:e8958. 2010
    ....
  74. ncbi Melanoma risk in congenital melanocytic naevi: a systematic review
    S Krengel
    Department of Dermatology, University of Kiel, Kiel, Germany
    Br J Dermatol 155:1-8. 2006
    ..The risk of malignant melanoma in congenital melanocytic naevi (CMN) is a matter of controversial and ongoing debate...
  75. ncbi Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data
    R M Szeimies
    Department of Dermatology, Regensburg University Hospital, Franz Josef Strauss Allee 11, Regensburg, Germany
    Br J Dermatol 162:410-4. 2010
    ..Photodynamic therapy with a self-adhesive 5-aminolaevulinic acid (5-ALA) patch shows high efficacy rates in the treatment of mild to moderate actinic keratosis (AK) in short term trials...
  76. pmc Immunotherapy of distant metastatic disease
    D Schadendorf
    Department of Dermatology, University Hospital Essen, Essen, Germany
    Ann Oncol 20:vi41-50. 2009
    ..Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed...
  77. doi Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    R Dummer
    Department of Dermatology, University of Kiel, Kiel, Germany
    Ann Oncol 19:ii86-8. 2008
  78. pmc Basal cell carcinoma-treatments for the commonest skin cancer
    Carola Berking
    Clinic and Policlinic for Dermatology and Allergology, Ludwig Maximilian University of Munich LMU, Department of Dermatology, Allergology and Venerology, University Medical Center Schleswig Holstein, Kiel, Department of Radiotherapy, University Medical Center Regensburg, Germany, Department of Oral and Maxillofacial Radiology, Clinic for Oral and Craniomaxillofacial Surgery, Ludwig Maximilians University of Munich LMU, Department of Dermatology and Allergology, Hannover Skin Cancer Center, Hannover Medical School
    Dtsch Arztebl Int 111:389-95. 2014
    ..It very rarely metastasizes. A variety of treatments are available for the different subtypes and stages of BCC...
  79. ncbi To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions
    Axel Hauschild
    University Hospital Schleswig Holstein UKSH, Campus Kiel, Kiel, Germany
    J Dtsch Dermatol Ges 12:606-14. 2014
    ..To determine the biopsy sensitivity to melanoma of dermatologists in Germany and the impact of MelaFind® on their decisions to biopsy melanomas...
  80. doi Long-term efficacy of subcutaneous sweat gland suction curettage for axillary hyperhidrosis: a prospective gravimetrically controlled study
    Stephanie Darabaneanu
    Institute of Medical Psychology, University of Kiel, Kiel, Germany
    Dermatol Surg 34:1170-7; discussion 1177. 2008
    ..Subcutaneous sweat gland suction curettage (SSGSC) is gaining acceptance as a therapy for axillary hyperhidrosis. Despite its acceptance, there remains a lack of prospective data describing the efficacy and long-term outcome of SSGSC...
  81. ncbi Cerebriform giant melanocytic nevus of the scalp: report of two cases with different surgical approaches
    Matthias Moehrle
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    Dermatol Surg 28:75-9. 2002
    ..The nevus also contained areas of fetid maceration. After implanting a tissue expander under general anesthesia the nevus was excised. The defect was closed using a rotation flap...
  82. doi [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients]
    K C Kähler
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig Holstein, Campus Kiel, 24105, Kiel, Deutschland
    Hautarzt 60:433-40. 2009
    ....
  83. doi [Immunmodulatory antibodies in the treatment of skin cancer]
    D Schrama
    Klinik fur Dermatologie, Allergologie und Venerologie, Universitätshautklinik Würzburg, Josef Schneider Strasse 2, 97080, Wurzburg, Deutschland
    Hautarzt 59:806-13. 2008
    ..The latter can be achieved by blockage of inhibitory signal pathways or stimulation of excitatory signal pathways of immune response. We discuss the immunomodulatory antibodies which are currently in clinical testing...
  84. pmc Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    A Hauschild
    Department of Dermatology, Christian Albrechts University, Kiel
    Br J Cancer 84:1036-42. 2001
    ..Further phase III trials with continuous infusion and higher dosages must be performed before any final conclusions can be drawn on the potential usefulness of IL-2 in biochemotherapy of advanced melanoma...
  85. ncbi Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin
    S Eiling
    Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, Germany
    Br J Dermatol 147:150-3. 2002
    ..Caelyx(R) appears to be a promising alternative to conventional treatment of cutaneous angiosarcoma...
  86. doi Melanomas of unknown primary frequently harbor TERT-promoter mutations
    Friederike Egberts
    Departments of aDermatology bPathology cObstetrics and Gynecology, Schleswig Holstein University Hospital, Campus Kiel, Kiel dDepartment of Otolaryngology, Head and Neck Surgery, Philipps University Marburg, Marburg, Germany
    Melanoma Res 24:131-6. 2014
    ..The TERT-promoter genotype of MUP points toward a cutaneous and not mucosal origin. The significant sex differences merit further attention in having putative therapeutic implications. ..
  87. ncbi Linear intraoral lesions in the sebaceous nevus syndrome
    Patrick H Warnke
    Department of Oral and Maxillofacial Surgery, University of Kiel, Kiel, Germany
    J Am Acad Dermatol 52:62-4. 2005
  88. ncbi Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP)
    T Schmook
    Department of Dermatology, University of Kiel, Germany
    Clin Exp Dermatol 28:31-3. 2003
    ..Follow-up biopsies on the forehead showed no evidence of CD20 positive lymphoma cells, now. Despite mild leucocytopaenia therapy was well tolerated...
  89. ncbi Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients
    C Schmitz
    Department of Dermatology at the University of Kiel, Schittenhelmstr 7, D 24105 Kiel, Germany
    Anticancer Res 20:5059-63. 2000
    ..We analysed the serum levels of S-100B and MIA in non-melanoma control patients and in melanoma patients in different stages of disease (stage I-IV) to report on the sensitivity and specificity of both tumor markers...
  90. ncbi [Sentinel lymph node biopsy]
    Axel Hauschild
    Hautarzt 56:888-9. 2005
  91. doi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  92. doi Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
    Paul Lorigan
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK
    Exp Dermatol 17:383-94. 2008
    ..This paper discusses the range of new drugs and targets have been identified, the outcome of clinical trials, and the directions for future advances...
  93. ncbi Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:61-7. 2008
    ..In distant metastases, radiation therapy is particularly indicated in bone metastases, brain metastases and soft tissue metastases...
  94. ncbi Installation of a network for patients with congenital melanocytic nevi in German-speaking countries
    Sven Krengel
    Dermatology Practice, Lubeck, Germany
    J Dtsch Dermatol Ges 6:204-8. 2008
    ..Recent findings from the literature and considerations from scientific meetings are reviewed...
  95. ncbi Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 17:393-9. 2007
    ..Additionally, in the stage of regional metastasis, whole body imaging should be performed every 6 months; in the stage of distant metastasis, surveillance has to be scheduled individually...
  96. ncbi Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma
    Ruth Oratz
    Department of Medical Oncology, New York University Medical Center, New York City, New York 10016, USA
    Melanoma Res 13:59-66. 2003
    ..In conclusion, cisplatin/adrenaline injectable gel was well tolerated, easy to administer, and effective in treating metastatic melanoma confined to the skin or soft tissues...
  97. ncbi Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha
    Imke Satzger
    Department of Dermatology and Allergology, Hannover Medical School, Hautklinik Linden, Klinikum Region Hannover, Skin Cancer Center Hannover, Hannover, Germany
    Int J Cancer 121:2562-6. 2007
    ..Thus, autoimmunity triggered by low-dose IFN therapy appears to indicate an improved prognosis and should encourage continuation of IFN therapy...
  98. ncbi In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group
    Selma Ugurel
    Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany
    Clin Cancer Res 12:5454-63. 2006
    ..This multicenter phase II trial was aimed to investigate the efficacy of a sensitivity-directed, first-line chemotherapy in metastasized melanoma patients, and to prove an association between in vitro sensitivity and therapy outcome...
  99. ncbi Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy
    Jens Michael Jensen
    Acta Derm Venereol 85:550-1. 2005
  100. ncbi Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes
    Soheil S Dadras
    Cutaneous Biology Research Center and Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Mod Pathol 18:1232-42. 2005
    ..Assessment of lymphangiogenesis in primary melanomas may be a more effective approach than the currently used technique of measuring tumor thickness in selecting patients with early metastatic disease for aggressive therapy...